ES2412306T3 - Polimorfos de 4-((4-cloro-2-hidroxibenzoil)amino)butanoato de sodio - Google Patents

Polimorfos de 4-((4-cloro-2-hidroxibenzoil)amino)butanoato de sodio Download PDF

Info

Publication number
ES2412306T3
ES2412306T3 ES10012220T ES10012220T ES2412306T3 ES 2412306 T3 ES2412306 T3 ES 2412306T3 ES 10012220 T ES10012220 T ES 10012220T ES 10012220 T ES10012220 T ES 10012220T ES 2412306 T3 ES2412306 T3 ES 2412306T3
Authority
ES
Spain
Prior art keywords
hydroxybenzoyl
butanoate
chloro
amino
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10012220T
Other languages
English (en)
Spanish (es)
Inventor
Satej Bhandarkar
Shingai Majuru
Halina Leuchyk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emisphere Technologies Inc
Original Assignee
Emisphere Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Technologies Inc filed Critical Emisphere Technologies Inc
Application granted granted Critical
Publication of ES2412306T3 publication Critical patent/ES2412306T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES10012220T 2002-01-09 2003-01-09 Polimorfos de 4-((4-cloro-2-hidroxibenzoil)amino)butanoato de sodio Expired - Lifetime ES2412306T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34761002P 2002-01-09 2002-01-09
US347610P 2002-01-09

Publications (1)

Publication Number Publication Date
ES2412306T3 true ES2412306T3 (es) 2013-07-11

Family

ID=23364463

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10012220T Expired - Lifetime ES2412306T3 (es) 2002-01-09 2003-01-09 Polimorfos de 4-((4-cloro-2-hidroxibenzoil)amino)butanoato de sodio
ES03719286.1T Expired - Lifetime ES2664189T3 (es) 2002-01-09 2003-01-09 Polimorfos de 4-(4-cloro-2-hidroxibenzoil)aminobutanoato de sodio

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES03719286.1T Expired - Lifetime ES2664189T3 (es) 2002-01-09 2003-01-09 Polimorfos de 4-(4-cloro-2-hidroxibenzoil)aminobutanoato de sodio

Country Status (7)

Country Link
US (5) US7227033B2 (enExample)
EP (2) EP1469827B1 (enExample)
JP (1) JP4508646B2 (enExample)
AU (1) AU2003223158B2 (enExample)
CA (1) CA2471144C (enExample)
ES (2) ES2412306T3 (enExample)
WO (1) WO2003057650A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344213B1 (en) 1996-03-29 2002-02-05 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6991798B1 (en) 1998-08-07 2006-01-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CZ303736B6 (cs) 2000-06-29 2013-04-17 Emisphere Technologies, Inc. Slouceniny a prostredky pro zavádení aktivních cinidel
US7227033B2 (en) 2002-01-09 2007-06-05 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate
US7384914B2 (en) * 2003-01-06 2008-06-10 Emisphere Technologies, Inc. Night-time oral insulin therapy
US20050203001A1 (en) * 2004-03-05 2005-09-15 Emisphere Technologies, Inc. Oral insulin therapies and protocol
US20050192298A1 (en) * 2004-02-27 2005-09-01 Pfizer Inc Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
NZ551196A (en) * 2004-05-14 2010-08-27 Emisphere Tech Inc Compounds and compositions for delivering active agents
AU2005244986B2 (en) 2004-05-19 2011-01-27 Emisphere Technologies, Inc. Topical cromolyn formulations
NZ551455A (en) 2004-05-19 2012-03-30 Emisphere Tech Inc Acyclovir formulations
EP2248531A1 (en) 2004-08-03 2010-11-10 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
FR2875807B1 (fr) * 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
GB0427603D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
GB0427600D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
AU2005321803B2 (en) 2004-12-29 2012-02-09 Emisphere Technologies, Inc. Pharmaceutical formulations of gallium salts
WO2006076692A1 (en) 2005-01-12 2006-07-20 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
US8030271B2 (en) 2005-07-05 2011-10-04 Emisphere Technologies, Inc. Compositions and methods for buccal delivery of human growth hormone
US9364502B2 (en) * 2006-06-28 2016-06-14 Emisphere Technologies, Inc. Gallium nitrate formulations
WO2011017346A2 (en) 2009-08-03 2011-02-10 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
CN104884065B (zh) 2012-09-21 2019-01-01 强烈治疗剂公司 治疗癌症的方法
EP2919804B1 (fr) 2012-11-13 2018-01-31 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
WO2020111139A1 (ja) * 2018-11-29 2020-06-04 Ｎｅｃソリューションイノベータ株式会社 座標算出装置、座標算出方法、及びコンピュータ読み取り可能な記録媒体
CN111925298B (zh) * 2020-09-02 2023-05-30 无锡紫杉药业有限公司 一种4-cnab及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5811856B2 (ja) * 1975-07-14 1983-03-04 中外製薬株式会社 ２ ４− ビス （２’ − アセトキシベンズアミド ） アンソクコウサンノ イケイケツシヨウノ セイゾウホウ
JPS5312417A (en) * 1976-07-20 1978-02-03 Sumitomo Chem Co Ltd Preparation of amorphous d rugs
US4421685A (en) 1980-03-27 1983-12-20 Eli Lilly And Company Process for producing an insulin
CA1214170A (fr) 1981-06-16 1986-11-18 Patrick Choay Procedes de preparation de nouveaux composes du type arylbenzenesulfonamide
USRE35862E (en) 1986-08-18 1998-07-28 Emisphere Technologies, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US5629020A (en) 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5443841A (en) 1992-06-15 1995-08-22 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US5583020A (en) 1992-11-24 1996-12-10 Ribozyme Pharmaceuticals, Inc. Permeability enhancers for negatively charged polynucleotides
US5401516A (en) 1992-12-21 1995-03-28 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DE69434418T2 (de) 1993-04-22 2005-12-22 Emisphere Technologies, Inc. Orale Dareichungsform
US5534488A (en) 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
JP3462895B2 (ja) * 1993-11-05 2003-11-05 三井化学株式会社 安息香酸誘導体の多価金属塩の製造方法
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
US5776888A (en) 1997-02-07 1998-07-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DK0993831T3 (da) 1997-02-07 2008-03-25 Emisphere Tech Inc Forbindelser og præparater til tilförsel af aktive stoffer
GB9808896D0 (en) 1998-04-25 1998-06-24 Smithkline Beecham Plc Novel compound
EP1956015B2 (en) * 1998-06-19 2018-11-14 Teijin Limited Polymorph of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same
AU5471199A (en) 1998-08-07 2000-02-28 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR0008590A (pt) 1999-01-08 2001-10-30 Emisphere Tech Inc Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
DE19903275A1 (de) * 1999-01-28 2000-08-03 Merck Patent Gmbh Lyophilisate mit verbesserter Rekonstituierbarkeit
ATE309197T1 (de) 1999-02-05 2005-11-15 Emisphere Tech Inc Verfahren zur herstellung alkylierter salicylamide
EP1163209A4 (en) 1999-02-26 2004-12-29 Emisphere Tech Inc COMPOUNDS AND COMPOSITIONS FOR ADMINISTRATION OF ACTIVE INGREDIENTS
CA2369591C (en) * 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
GB9923934D0 (en) * 1999-10-08 1999-12-08 Smithkline Beecham Plc Novel pharmaceutical
GB9923933D0 (en) * 1999-10-08 1999-12-08 Smithkline Beecham Lab Novel pharmaceutical
WO2001032130A2 (en) 1999-11-05 2001-05-10 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
JP2001240581A (ja) * 2000-02-29 2001-09-04 Senju Pharmaceut Co Ltd アミノベンズアミド誘導体およびその用途
ES2386263T3 (es) 2000-03-21 2012-08-14 Emisphere Technologies, Inc. Método de preparación de salicilamidas alquiladas mediante un producto intermedio de dicarboxilato
US7227033B2 (en) 2002-01-09 2007-06-05 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate
CZ303736B6 (cs) 2000-06-29 2013-04-17 Emisphere Technologies, Inc. Slouceniny a prostredky pro zavádení aktivních cinidel
US6482847B2 (en) * 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability

Also Published As

Publication number Publication date
WO2003057650A3 (en) 2003-10-16
AU2003223158A1 (en) 2003-07-24
EP1469827A4 (en) 2006-08-16
ES2664189T3 (es) 2018-04-18
CA2471144A1 (en) 2003-07-17
AU2003223158B2 (en) 2008-01-17
CA2471144C (en) 2011-06-07
EP1469827A2 (en) 2004-10-27
WO2003057650A2 (en) 2003-07-17
US20070161708A1 (en) 2007-07-12
US20090010882A1 (en) 2009-01-08
HK1153136A1 (en) 2012-03-23
US7208178B2 (en) 2007-04-24
US7227033B2 (en) 2007-06-05
EP1469827B1 (en) 2017-12-27
US7420085B2 (en) 2008-09-02
US20050272639A1 (en) 2005-12-08
US20080033204A1 (en) 2008-02-07
EP2272501B1 (en) 2013-03-20
US20050250852A1 (en) 2005-11-10
JP2005520803A (ja) 2005-07-14
US7893297B2 (en) 2011-02-22
US7462368B2 (en) 2008-12-09
EP2272501A1 (en) 2011-01-12
JP4508646B2 (ja) 2010-07-21

Similar Documents

Publication Publication Date Title
ES2412306T3 (es) Polimorfos de 4-((4-cloro-2-hidroxibenzoil)amino)butanoato de sodio
IS2896B (is) Gerviaugasteinn
NO20022649L (no) Heterocykliske dihydropyrimidiner som kaliumkanal inhibitorer
DE60300824D1 (de) Laserprojektionssystem
DK1947501T3 (da) Elektroaktivt kontaktlinsesystem
ATE397925T1 (de) Cis-imidazoline als mdm2-hemmer
NO20014642L (no) Aminopyrimidiner som sorbitol-dehydrogenase-inhibitorer
ATE493406T1 (de) Hydantoinderivate als mmp-inhibitoren
DE60330227D1 (de) N3-alkylierte benzimidazol-derivate als mek-hemmer
DE60334100D1 (de) Rückspiegelanordnungen
ATE363463T1 (de) 2-(2,6-dichlorphenyl)-diarylimidazole
UY3462Q (es) Dentifrico
ITMI20020908A0 (it) Processo di preparazione di sodio alendronato
DE60311340T8 (de) Optischer Schalter
DE60331752D1 (de) Linsenhaltegestell
UY3457Q (es) Dentifrico
UY3455Q (es) Dentifrico
UY3461Q (es) Dentifrico
EP1422543A4 (en) PROJECTION LENS
DK1347044T3 (da) Alkalisk protease
ATE410428T1 (de) Pyrroloä2,1-cüä1,4übenzodiazepine als vasopressin-agonisten
DE60307196D1 (de) Optisches Abtastgerät
DE60336790D1 (de) Optisches Vermittlungssystem
DE60334211D1 (de) Objektivlinsentreiber
DE60309543D1 (de) Optischer Verstärker